Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Annovis Bio Inc (NY: ANVS ) 6.650 UNCHANGED Streaming Delayed Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 20,520 Open 6.650 Bid (Size) 6.740 (2) Ask (Size) 6.760 (1) Prev. Close 6.650 Today's Range 6.650 - 6.650 52wk Range 4.530 - 22.49 Shares Outstanding 13,797,242 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Research Suggests Cancer Survivors are Less Prone to Alzheimer’s Development November 21, 2024 Via Investor Brand Network BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Paving the Way for NDA Submission November 19, 2024 Via Investor Brand Network Performance YTD -64.87% -64.87% 1 Month -32.62% -32.62% 3 Month -31.23% -31.23% 6 Month N/A N/A 1 Year -10.01% -10.01% More News Read More Annovis Bio Inc. (NYSE: ANVS) Concludes Q3 with Strategic Milestones and FDA-Cleared Phase 3 Program for Alzheimer’s Disease November 13, 2024 Via Investor Brand Network BioMedNewsBreaks – Annovis Bio Inc. CEO to Showcase Buntanetap’s Dual Benefits for Alzheimer’s and Parkinson’s at NIA Workshop November 12, 2024 Via Investor Brand Network BioMedNewsBreaks — Annovis Bio Inc. Advances Alzheimer’s Phase 3 Trials with Strong FDA Support and Financial Backing November 11, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety BioMedNewsBreaks — Annovis Bio Inc. Strengthens Clinical Research Team with Appointment of Senior Clinical Scientist November 07, 2024 Via Investor Brand Network Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease (‘CTAD’) 2024 Conference November 05, 2024 Via Investor Brand Network Study Explores How Antimicrobials Impact the Risk of Developing Parkinson’s Disease November 01, 2024 Via Investor Brand Network BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Details Promising Phase 3 Path for Alzheimer’s Treatment on The BioMedWire Podcast October 31, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients October 29, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies, Paving the Way for NDA Filings October 23, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Key Alzheimer’s Research at CTAD Conference in Madrid October 22, 2024 Via Investor Brand Network Analysis of Medical Records Repeatedly Links Viruses to Alzheimer’s October 16, 2024 Via Investor Brand Network BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance for Pivotal Phase 3 Alzheimer’s Trial, Launch Set for Early 2025 October 15, 2024 Via Investor Brand Network Exposures Product Safety Annovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative Diseases October 04, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More October 03, 2024 Via Investor Brand Network Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More October 03, 2024 Via FinancialNewsMedia Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition October 01, 2024 Via Investor Brand Network Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition October 01, 2024 Via FinancialNewsMedia BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD September 30, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Addressing Vision Problems Could Lower Risk of Dementia, Study Finds September 27, 2024 Via Investor Brand Network Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference September 25, 2024 Via Investor Brand Network BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap September 20, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Expert Says Alzheimer’s Disease Could Be an Autoimmune Illness September 06, 2024 Via Investor Brand Network BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference September 05, 2024 Via Investor Brand Network Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
